The new FDA Office are financed by a fee be paid made by tobacco companies.

While estimates show that at the time of approval comparative efficacy data are available for 50 percent to 70 percent of new drugs are available, the researchers argue that this varies in therapeutic areas and only a small %age of evidence is often the the time available to the marketing authorization for.

To write the researchers The European Medicines Agency has been long encouraged, where possible, be carried out prior to launch studies to establish comparable efficacy and risks, but still has comparative evaluation as the default evidential standard for market approval. . Continue reading “The new FDA Office are financed by a fee be paid made by tobacco companies.”